Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims Database
PURPOSEIn patients with cancer, aggressive treatment near the end of life (EOL) may decrease quality of life and increase medical costs. In this study, we examined the use of anticancer therapies near the EOL in Japan.METHODSWe used a commercial database of health insurance claims in Japan, to exami...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society of Clinical Oncology
2022-11-01
|
| Series: | JCO Global Oncology |
| Online Access: | https://ascopubs.org/doi/10.1200/GO.22.00227 |
| _version_ | 1798014558921555968 |
|---|---|
| author | Yusuke Kajimoto Kazunori Honda Kazuki Nozawa Mineko Mukai Lida Teng Ataru Igarashi |
| author_facet | Yusuke Kajimoto Kazunori Honda Kazuki Nozawa Mineko Mukai Lida Teng Ataru Igarashi |
| author_sort | Yusuke Kajimoto |
| collection | DOAJ |
| description | PURPOSEIn patients with cancer, aggressive treatment near the end of life (EOL) may decrease quality of life and increase medical costs. In this study, we examined the use of anticancer therapies near the EOL in Japan.METHODSWe used a commercial database of health insurance claims in Japan, to examine patient data on cancer and death until August 2020. We assessed the proportion of patients using anticancer therapies within 14 days of death, associated factors, and medical costs from the payer's perspective.RESULTSThe database documented 5,759 patients with cancer who died between December 2013 and August 2020. Among them, 4.8% of patients and 3.9% of age-adjusted patients received anticancer therapy within 14 days of death. Patients age < 60 years were associated with a high probability of receiving anticancer therapy near the EOL. The estimated annual anticancer therapy and related costs were Japanese yen 1,296 million (US dollars 12.6 million).CONCLUSIONWe found the percentage of patients receiving anticancer therapies within 14 days of death in Japan, its associated factors, and economic burden. Our findings can serve as a benchmark for optimizing EOL care. |
| first_indexed | 2024-04-11T15:19:34Z |
| format | Article |
| id | doaj.art-98f45c623b0e435ea5529c1d41d6fc3f |
| institution | Directory Open Access Journal |
| issn | 2687-8941 |
| language | English |
| last_indexed | 2024-04-11T15:19:34Z |
| publishDate | 2022-11-01 |
| publisher | American Society of Clinical Oncology |
| record_format | Article |
| series | JCO Global Oncology |
| spelling | doaj.art-98f45c623b0e435ea5529c1d41d6fc3f2022-12-22T04:16:24ZengAmerican Society of Clinical OncologyJCO Global Oncology2687-89412022-11-01810.1200/GO.22.00227Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims DatabaseYusuke Kajimoto0Kazunori Honda1Kazuki Nozawa2Mineko Mukai3Lida Teng4Ataru Igarashi5Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, JapanDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, JapanDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, JapanNursing Department, Aichi Cancer Center Hospital, Nagoya, JapanDepartment of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, JapanDepartment of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, JapanPURPOSEIn patients with cancer, aggressive treatment near the end of life (EOL) may decrease quality of life and increase medical costs. In this study, we examined the use of anticancer therapies near the EOL in Japan.METHODSWe used a commercial database of health insurance claims in Japan, to examine patient data on cancer and death until August 2020. We assessed the proportion of patients using anticancer therapies within 14 days of death, associated factors, and medical costs from the payer's perspective.RESULTSThe database documented 5,759 patients with cancer who died between December 2013 and August 2020. Among them, 4.8% of patients and 3.9% of age-adjusted patients received anticancer therapy within 14 days of death. Patients age < 60 years were associated with a high probability of receiving anticancer therapy near the EOL. The estimated annual anticancer therapy and related costs were Japanese yen 1,296 million (US dollars 12.6 million).CONCLUSIONWe found the percentage of patients receiving anticancer therapies within 14 days of death in Japan, its associated factors, and economic burden. Our findings can serve as a benchmark for optimizing EOL care.https://ascopubs.org/doi/10.1200/GO.22.00227 |
| spellingShingle | Yusuke Kajimoto Kazunori Honda Kazuki Nozawa Mineko Mukai Lida Teng Ataru Igarashi Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims Database JCO Global Oncology |
| title | Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims Database |
| title_full | Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims Database |
| title_fullStr | Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims Database |
| title_full_unstemmed | Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims Database |
| title_short | Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims Database |
| title_sort | use of anticancer therapies and economic burden near the end of life in japan results from claims database |
| url | https://ascopubs.org/doi/10.1200/GO.22.00227 |
| work_keys_str_mv | AT yusukekajimoto useofanticancertherapiesandeconomicburdenneartheendoflifeinjapanresultsfromclaimsdatabase AT kazunorihonda useofanticancertherapiesandeconomicburdenneartheendoflifeinjapanresultsfromclaimsdatabase AT kazukinozawa useofanticancertherapiesandeconomicburdenneartheendoflifeinjapanresultsfromclaimsdatabase AT minekomukai useofanticancertherapiesandeconomicburdenneartheendoflifeinjapanresultsfromclaimsdatabase AT lidateng useofanticancertherapiesandeconomicburdenneartheendoflifeinjapanresultsfromclaimsdatabase AT ataruigarashi useofanticancertherapiesandeconomicburdenneartheendoflifeinjapanresultsfromclaimsdatabase |